Table 2. Open in new tab Six-Month Rates...

	Herpes Zoster Cases	% Herpes Zoster Cases With Persistent Post-Zoster Pain
Total study population
Enrollees in group	44 460	264 397	5.97	(5.75–6.19)	3.93	(3.86–4.01)	<.01
Sex
Females	25 569	165 776	6.12	(5.83–6.42)	4.07	(3.98–4.17)	<.01
Males	18 891	98 621	5.77	(5.44–6.11)	3.69	(3.57–3.81)	<.01
Age group
18–49 years	7685	111 980	3.55	(3.16–3.99)	1.85	(1.77–1.93)	<.01
50–59 years	15 125	78 084	4.70	(4.38–5.05)	3.60	(3.47–3.73)	<.01
60–64 years	8862	32 200	5.26	(4.81–5.74)	4.69	(4.47–4.93)	.03
≥65 years	12 788	42 133	9.42	(8.92–9.93)	9.50	(9.22–9.78)	.80
Immune competent
Enrollees in group	40 998	247 371	5.84	(5.62–6.08)	3.77	(3.70–3.85)	<.01
Sex
Females	23 582	154 677	6.06	(5.76–6.37)	3.94	(3.85–4.04)	<.01
Males	17 416	92 694	5.55	(5.22–5.90)	3.49	(3.37–3.61)	<.01
Age group
18–49 years	7203	107 475	3.49	(3.09–3.93)	1.79	(1.71–1.87)	<.01
50–59 years	14 069	73 031	4.56	(4.23–4.92)	3.49	(3.36–3.62)	<.01
60–64 years	8155	29 507	5.15	(4.69–5.65)	4.65	(4.41–4.89)	.07
≥65 years	11 571	37 358	9.36	(8.84–9.90)	9.34	(9.05–9.64)	.94
Immune compromised
Enrollees in group	3462	17 026	7.46	(6.63–8.38)	6.25	(5.89–6.62)	<.01
Sex
Females	1987	11 099	6.85	(5.82–8.04)	5.91	(5.49–6.37)	.09
Males	1475	5927	8.28	(6.98–9.79)	6.87	(6.26–7.54)	.05
Age group
18–49 years	482	4505	4.56	(3.03–6.80)	3.31	(2.83–3.87)	.15
50–59 years	1056	5053	6.55	(5.20–8.20)	5.17	(4.59–5.81)	.06
60–64 years	707	2693	6.52	(4.92–8.58)	5.20	(4.42–6.10)	.14
≥65 years	1217	4775	9.94	(8.38–11.75)	10.75	(9.90–11.66)	.43

Herpes Zoster Cases

% Herpes Zoster Cases With Persistent Post-Zoster Pain

Diabetic Individuals

Nondiabetic Individuals

Diabetic Individuals

Nondiabetic Individuals

Difference

95% Confidence Interval [CI]

95% CI

P Value*

Total study population

Enrollees in group

44 460

264 397

5.97

(5.75–6.19)

3.93

(3.86–4.01)

<.01

Sex

Females

25 569

165 776

6.12

(5.83–6.42)

4.07

(3.98–4.17)

<.01

Males

18 891

98 621

5.77

(5.44–6.11)

3.69

(3.57–3.81)

<.01

Age group

18–49 years

7685

111 980

3.55

(3.16–3.99)

1.85

(1.77–1.93)

<.01

50–59 years

15 125

78 084

4.70

(4.38–5.05)

3.60

(3.47–3.73)

<.01

60–64 years

8862

32 200

5.26

(4.81–5.74)

4.69

(4.47–4.93)

.03

≥65 years

12 788

42 133

9.42

(8.92–9.93)

9.50

(9.22–9.78)

.80

Immune competent

Enrollees in group

40 998

247 371

5.84

(5.62–6.08)

3.77

(3.70–3.85)

<.01

Sex

Females

23 582

154 677

6.06

(5.76–6.37)

3.94

(3.85–4.04)

<.01

Males

17 416

92 694

5.55

(5.22–5.90)

3.49

(3.37–3.61)

<.01

Age group

18–49 years

7203

107 475

3.49

(3.09–3.93)

1.79

(1.71–1.87)

<.01

50–59 years

14 069

73 031

4.56

(4.23–4.92)

3.49

(3.36–3.62)

<.01

60–64 years

8155

29 507

5.15

(4.69–5.65)

4.65

(4.41–4.89)

.07

≥65 years

11 571

37 358

9.36

(8.84–9.90)

9.34

(9.05–9.64)

.94

Immune compromised

Enrollees in group

3462

17 026

7.46

(6.63–8.38)

6.25

(5.89–6.62)

<.01

Sex

Females

1987

11 099

6.85

(5.82–8.04)

5.91

(5.49–6.37)

.09

Males

1475

5927

8.28

(6.98–9.79)

6.87

(6.26–7.54)

.05

Age group

18–49 years

482

4505

4.56

(3.03–6.80)

3.31

(2.83–3.87)

.15

50–59 years

1056

5053

6.55

(5.20–8.20)

5.17

(4.59–5.81)

.06

60–64 years

707

2693

6.52

(4.92–8.58)

5.20

(4.42–6.10)

.14

≥65 years

1217

4775

9.94

(8.38–11.75)

10.75

(9.90–11.66)

.43

	Herpes Zoster Cases	% Herpes Zoster Cases With Persistent Post-Zoster Pain
Total study population
Enrollees in group	44 460	264 397	5.97	(5.75–6.19)	3.93	(3.86–4.01)	<.01
Sex
Females	25 569	165 776	6.12	(5.83–6.42)	4.07	(3.98–4.17)	<.01
Males	18 891	98 621	5.77	(5.44–6.11)	3.69	(3.57–3.81)	<.01
Age group
18–49 years	7685	111 980	3.55	(3.16–3.99)	1.85	(1.77–1.93)	<.01
50–59 years	15 125	78 084	4.70	(4.38–5.05)	3.60	(3.47–3.73)	<.01
60–64 years	8862	32 200	5.26	(4.81–5.74)	4.69	(4.47–4.93)	.03
≥65 years	12 788	42 133	9.42	(8.92–9.93)	9.50	(9.22–9.78)	.80
Immune competent
Enrollees in group	40 998	247 371	5.84	(5.62–6.08)	3.77	(3.70–3.85)	<.01
Sex
Females	23 582	154 677	6.06	(5.76–6.37)	3.94	(3.85–4.04)	<.01
Males	17 416	92 694	5.55	(5.22–5.90)	3.49	(3.37–3.61)	<.01
Age group
18–49 years	7203	107 475	3.49	(3.09–3.93)	1.79	(1.71–1.87)	<.01
50–59 years	14 069	73 031	4.56	(4.23–4.92)	3.49	(3.36–3.62)	<.01
60–64 years	8155	29 507	5.15	(4.69–5.65)	4.65	(4.41–4.89)	.07
≥65 years	11 571	37 358	9.36	(8.84–9.90)	9.34	(9.05–9.64)	.94
Immune compromised
Enrollees in group	3462	17 026	7.46	(6.63–8.38)	6.25	(5.89–6.62)	<.01
Sex
Females	1987	11 099	6.85	(5.82–8.04)	5.91	(5.49–6.37)	.09
Males	1475	5927	8.28	(6.98–9.79)	6.87	(6.26–7.54)	.05
Age group
18–49 years	482	4505	4.56	(3.03–6.80)	3.31	(2.83–3.87)	.15
50–59 years	1056	5053	6.55	(5.20–8.20)	5.17	(4.59–5.81)	.06
60–64 years	707	2693	6.52	(4.92–8.58)	5.20	(4.42–6.10)	.14
≥65 years	1217	4775	9.94	(8.38–11.75)	10.75	(9.90–11.66)	.43

Table 2.

Open in new tab

Six-Month Rates of Persistent Post-Zoster Pain by Diabetes and Concomitant Immune-Compromised Status, 2005–2009

	Herpes Zoster Cases		% Herpes Zoster Cases With Persistent Post-Zoster Pain
	Diabetic Individuals	Nondiabetic Individuals	Diabetic Individuals		Nondiabetic Individuals		Difference
	N	N	%	95% Confidence Interval [CI]	%	95% CI	P Value*
Total study population
Enrollees in group	44 460	264 397	5.97	(5.75–6.19)	3.93	(3.86–4.01)	<.01
Sex
Females	25 569	165 776	6.12	(5.83–6.42)	4.07	(3.98–4.17)	<.01
Males	18 891	98 621	5.77	(5.44–6.11)	3.69	(3.57–3.81)	<.01
Age group
18–49 years	7685	111 980	3.55	(3.16–3.99)	1.85	(1.77–1.93)	<.01
50–59 years	15 125	78 084	4.70	(4.38–5.05)	3.60	(3.47–3.73)	<.01
60–64 years	8862	32 200	5.26	(4.81–5.74)	4.69	(4.47–4.93)	.03
≥65 years	12 788	42 133	9.42	(8.92–9.93)	9.50	(9.22–9.78)	.80
Immune competent
Enrollees in group	40 998	247 371	5.84	(5.62–6.08)	3.77	(3.70–3.85)	<.01
Sex
Females	23 582	154 677	6.06	(5.76–6.37)	3.94	(3.85–4.04)	<.01
Males	17 416	92 694	5.55	(5.22–5.90)	3.49	(3.37–3.61)	<.01
Age group
18–49 years	7203	107 475	3.49	(3.09–3.93)	1.79	(1.71–1.87)	<.01
50–59 years	14 069	73 031	4.56	(4.23–4.92)	3.49	(3.36–3.62)	<.01
60–64 years	8155	29 507	5.15	(4.69–5.65)	4.65	(4.41–4.89)	.07
≥65 years	11 571	37 358	9.36	(8.84–9.90)	9.34	(9.05–9.64)	.94
Immune compromised
Enrollees in group	3462	17 026	7.46	(6.63–8.38)	6.25	(5.89–6.62)	<.01
Sex
Females	1987	11 099	6.85	(5.82–8.04)	5.91	(5.49–6.37)	.09
Males	1475	5927	8.28	(6.98–9.79)	6.87	(6.26–7.54)	.05
Age group
18–49 years	482	4505	4.56	(3.03–6.80)	3.31	(2.83–3.87)	.15
50–59 years	1056	5053	6.55	(5.20–8.20)	5.17	(4.59–5.81)	.06
60–64 years	707	2693	6.52	(4.92–8.58)	5.20	(4.42–6.10)	.14
≥65 years	1217	4775	9.94	(8.38–11.75)	10.75	(9.90–11.66)	.43

	Herpes Zoster Cases		% Herpes Zoster Cases With Persistent Post-Zoster Pain
	Diabetic Individuals	Nondiabetic Individuals	Diabetic Individuals		Nondiabetic Individuals		Difference
	N	N	%	95% Confidence Interval [CI]	%	95% CI	P Value*
Total study population
Enrollees in group	44 460	264 397	5.97	(5.75–6.19)	3.93	(3.86–4.01)	<.01
Sex
Females	25 569	165 776	6.12	(5.83–6.42)	4.07	(3.98–4.17)	<.01
Males	18 891	98 621	5.77	(5.44–6.11)	3.69	(3.57–3.81)	<.01
Age group
18–49 years	7685	111 980	3.55	(3.16–3.99)	1.85	(1.77–1.93)	<.01
50–59 years	15 125	78 084	4.70	(4.38–5.05)	3.60	(3.47–3.73)	<.01
60–64 years	8862	32 200	5.26	(4.81–5.74)	4.69	(4.47–4.93)	.03
≥65 years	12 788	42 133	9.42	(8.92–9.93)	9.50	(9.22–9.78)	.80
Immune competent
Enrollees in group	40 998	247 371	5.84	(5.62–6.08)	3.77	(3.70–3.85)	<.01
Sex
Females	23 582	154 677	6.06	(5.76–6.37)	3.94	(3.85–4.04)	<.01
Males	17 416	92 694	5.55	(5.22–5.90)	3.49	(3.37–3.61)	<.01
Age group
18–49 years	7203	107 475	3.49	(3.09–3.93)	1.79	(1.71–1.87)	<.01
50–59 years	14 069	73 031	4.56	(4.23–4.92)	3.49	(3.36–3.62)	<.01
60–64 years	8155	29 507	5.15	(4.69–5.65)	4.65	(4.41–4.89)	.07
≥65 years	11 571	37 358	9.36	(8.84–9.90)	9.34	(9.05–9.64)	.94
Immune compromised
Enrollees in group	3462	17 026	7.46	(6.63–8.38)	6.25	(5.89–6.62)	<.01
Sex
Females	1987	11 099	6.85	(5.82–8.04)	5.91	(5.49–6.37)	.09
Males	1475	5927	8.28	(6.98–9.79)	6.87	(6.26–7.54)	.05
Age group
18–49 years	482	4505	4.56	(3.03–6.80)	3.31	(2.83–3.87)	.15
50–59 years	1056	5053	6.55	(5.20–8.20)	5.17	(4.59–5.81)	.06
60–64 years	707	2693	6.52	(4.92–8.58)	5.20	(4.42–6.10)	.14
≥65 years	1217	4775	9.94	(8.38–11.75)	10.75	(9.90–11.66)	.43

* P value for the difference between the risks was based on Fisher's exact test.

This Feature Is Available To Subscribers Only